Amylyx Pharmaceuticals, Inc. Increase Decrease In Operating Lease Liability
Amylyx Pharmaceuticals, Inc. (AMLX) reported Increase Decrease In Operating Lease Liability of -$702.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$375.00K.
- Amylyx Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$327.00K.
- Amylyx Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $23.00K.
- Amylyx Pharmaceuticals, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$27.00K.
- Amylyx Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.16M.
- Amylyx Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2024 was -$2.26M.
- Amylyx Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2023 was -$2.04M.
- Amylyx Pharmaceuticals, Inc. increase decrease in operating lease liability for fiscal 2022 was -$917.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$375.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$702.00K 10-Q · filed 2026-08-06 | -$679.00K derived: sum of 3 quarters · filed 2026-08-06 | -$706.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$327.00K 10-Q · filed 2026-05-07 | -$304.00K derived: sum of 2 quarters · filed 2026-05-07 | -$331.00K derived: sum of 3 quarters · filed 2026-05-07 | -$890.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$4.00K derived: sum of 2 quarters · filed 2026-03-03 | -$563.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.16M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$586.00K derived: sum of 2 quarters · filed 2026-08-06 | -$1.19M 10-Q · filed 2025-11-06 | -$1.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$559.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.16M 10-Q · filed 2026-08-06 | -$1.74M derived: sum of 3 quarters · filed 2026-08-06 | -$2.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$599.00K 10-Q · filed 2026-05-07 | -$1.19M derived: sum of 2 quarters · filed 2026-05-07 | -$1.76M derived: sum of 3 quarters · filed 2026-05-07 | -$2.31M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$586.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$1.16M derived: sum of 2 quarters · filed 2026-03-03 | -$1.71M derived: sum of 3 quarters · filed 2026-03-03 | -$2.26M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$574.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.13M derived: sum of 2 quarters · filed 2025-11-06 | -$1.67M 10-Q · filed 2025-11-06 | -$2.20M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$553.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.10M 10-Q · filed 2025-08-07 | -$1.63M derived: sum of 3 quarters · filed 2025-08-07 | -$2.15M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$543.00K 10-Q · filed 2025-05-08 | -$1.07M derived: sum of 2 quarters · filed 2025-05-08 | -$1.59M derived: sum of 3 quarters · filed 2025-05-08 | -$2.09M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$532.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$1.05M derived: sum of 2 quarters · filed 2025-03-04 | -$1.55M derived: sum of 3 quarters · filed 2025-03-04 | -$2.04M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$519.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.02M derived: sum of 2 quarters · filed 2024-11-07 | -$1.51M 10-Q · filed 2024-11-07 | -$1.99M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$990.00K 10-Q · filed 2024-08-08 | -$1.47M derived: sum of 3 quarters · filed 2024-08-08 | -$1.79M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$491.00K 10-Q · filed 2024-05-09 | -$972.00K derived: sum of 2 quarters · filed 2024-05-09 | -$1.29M derived: sum of 3 quarters · filed 2024-05-09 | -$1.41M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$481.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$797.00K derived: sum of 2 quarters · filed 2024-02-22 | -$914.00K derived: sum of 3 quarters · filed 2024-02-22 | -$917.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | -$316.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$433.00K derived: sum of 2 quarters · filed 2023-11-09 | -$436.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$117.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$120.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$3.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |